Text Size

Autologous T Cell Vaccine (TCV) for Multiple Sclerosis (TERMS)

This study has been completed.
Sponsor:
Information provided by:
Opexa Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT00245622
First received: October 20, 2005
Last updated: June 27, 2011
Last verified: June 2011
History of Changes
  Purpose

This is a 1 year study to evaluate the efficacy, safety, and tolerability of Tovaxin T cell therapy in subjects with a clinically isolated syndrome (CIS) and relapse-remitting multiple sclerosis (RR-MS).


Condition Intervention Phase
Relapsing-Remitting Multiple Sclerosis
 Biological: Tovaxin Autologous T cell vaccine
Biological: Placebo
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Subcutaneous Tovaxin in Subjects With CIS or RR-MS

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Opexa Therapeutics, Inc.:

Primary Outcome Measures:
  • To evaluate the efficacy, safety, and tolerability of Tovaxin TCV in subjects with CIS or RR-MS [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To evaluate biomarkers of efficacy of Tovaxin TCV and effects of Tovaxin TCV on epitope spreading [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Enrollment: 150
Study Start Date: May 2006
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
2.0 mL subcutaneous formulated with 30-45 million autologous myelin reactive T cells
 Biological: Tovaxin Autologous T cell vaccine
subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
Placebo Comparator: 2
2.0 mL subcutaneous injections without autologous myelin reactive T cells
 Biological: Placebo
subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24

Detailed Description:

A 2 arm, 52 week parallel-group of Tovaxin versus placebo in subjects with CIS or RR-MS. Subjects who provide written, informed consent will complete screening and procurement assessments and provide blood to be used for vaccine production. Eligible subjects will be enrolled to receive either Tovaxin or placebo and will complete baseline assessments. Randomization and enrolled subjects will receive study treatment by subcutaneous injections at weeks 0, 4, 8, 12, and 24. Subjects will be monitored by CBC, serum chemistries, urinalysis, Expanded Disability Status Scale (EDSS), MSFC, MSQLI, magnetic resonance imaging (MRI), and monitor myelin reactive T cells for safety, efficacy, and tolerability of Tovaxin.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Aged 18 to 55 years old
  • Presence of myelin reactive T cells at screening
  • Diagnosis of CIS with screening MRI that fulfils the Barkhof criteria - dissemination in space
  • Diagnosis of MS within the past 10 years according to the McDonald criteria (2005)
  • Baseline EDSS score between 0 and 5.5 inclusively

Exclusion Criteria:

  • Unable to produce T cell vaccine
  • Disease-modifying treatment for MS during the last 30 days and 60 days for steroidal treatments
  • Diagnosis of progressive-relapsing, secondary progressive, or primary progressive MS
  • Planned pregnancy, currently pregnant, or breastfeeding
  • Any prior treatment with total lymphoid irradiation, cladribine, T cell or T cell receptor vaccination
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00245622

  Show 33 Study Locations
Sponsors and Collaborators
Opexa Therapeutics, Inc.
Investigators
Study Chair: Edward J Fox, M.D., Ph.D. Central Texas Neurology Consultants
Study Director: Jaye Thompson, Ph.D. Opexa Therapeutics, Inc.
  More Information

Additional Information:
Sponsor's website  This link exits the ClinicalTrials.gov site

Publications:
Fox E, Markowitz C, Cohan S, Wynn D. TERMS Trial TCV Secondary Analysis of Clinical and Immunological Outcoms in Patients with Relapsing Remitting MS. Poster presentation P06.132 at the 61st Annual Meeting of the American Academy of Neurology (AAN) on 01 May 2009.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Jaye Thompson, PhD, Opexa Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT00245622     History of Changes
Other Study ID Numbers: 2005-00
Study First Received: October 20, 2005
Last Updated: June 27, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Opexa Therapeutics, Inc.:
Phase 2b Tovaxin
Clinically Isolated Syndrome (CIS)
Relapse-Remitting Multiple Sclerosis (RR-MS)

Additional relevant MeSH terms:
Multiple Sclerosis
Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
 Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on May 19, 2013